November 7th 2022
The study authors maintain there is no current evidence in the literature indicating that CT use is superior to other imaging modalities in reducing morbidity or improving outcomes in patients with urinary stone disease.
Recent study associates unmet social needs with urologic conditions
March 31st 2022Elisabeth M. Sebesta, MD, coauthor of a recent study, reported that patients who experienced more unmet social needs were at increased risk of multiple urologic conditions, such as overactive bladder, interstitial cystitis, or urge incontinence.
Study investigates mindfulness-based stress reduction for urodynamics
March 23rd 2022In this interview, Andrea Staack, MD, PhD, discusses the background, findings, and takeaways of the study, "Mindfulness based-stress reduction is associated with decreased levels of patients’ anxiety after urodynamics- A prospective randomized controlled trial," along with why urologists should consider implementing more strategies of this effect in their practices.
Optilume drug-coated balloon superior to standard care for recurrent anterior urethral strictures
October 14th 2021“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.
iTind device improves urinary function while preserving sexual function
January 18th 2021Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.
5-year data sustain water vapor thermal therapy benefit in BPH-related LUTS
July 30th 2020Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Sulopenem hits key end point in phase 3 uncomplicated UTI trial
June 29th 2020The novel oral penem anti-infective compound sulopenem showed stronger clinical activity than ciprofloxacin in patients with uncomplicated urinary tract infections with quinolone resistant pathogens, according to findings from the phase 3 SURE1 trial.